Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 3/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.51 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.51 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.51 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.45 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.45 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ddctp SCHEMBL30586989 | 0.98 | POLG (0.70) | POLGPOLBP2RY2P2RY6P2RY4 | |
| Ddctp SCHEMBL20879464 | 0.98 | POLG (0.70) | POLGPOLBP2RY2P2RY6P2RY4 | |
| Ddctp SCHEMBL210922 | 0.98 | POLG (0.70) | POLGPOLBP2RY2P2RY6P2RY4 | |
| Ddctp SCHEMBL16807754 | 0.98 | POLG (0.70) | POLGPOLBP2RY2P2RY6P2RY4 | |
| Ddctp SCHEMBL18840498 | 0.98 | POLG (0.70) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL543055 | 0.93 | POLG (0.60) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL543054 | 0.93 | POLG (0.60) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL23157216 | 0.91 | POLG (0.55) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL21895844 | 0.91 | POLG (0.55) | POLGPOLBP2RY2P2RY6P2RY4 | |
| SCHEMBL23157013 | 0.91 | POLG (0.55) | POLGPOLBP2RY2P2RY6P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | Insignis Therapeutics, Inc. | 2025-01-02 | — | — | US | disclosed |
| CN-118957031-A | Method for detecting mutant DNA and kit for detecting mutant DNA | 中元汇吉生物技术股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-111565716-B | Method of using dipivefrin | 因斯格尼斯疗法有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | INSIGNIS THERAPEUTICS INC (US) | 2022-06-23 | — | — | US | disclosed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2011-05-19 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| EP-1240355-B1 | REMOVAL OF DYE-LABELED DIDEOXY TERMINATORS FROM DNA SEQUENCING REACTIONS | CAMBREX BIO SCIENCE ROCKLAND I (US) | 2008-08-27 | — | — | EP | disclosed |
| EP-1778254-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | Protera S.R.L. (IT) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006013203-A2 | PRODRUGS ACTIVATED BY RNA-DEPENDENT DNA-POLYMERASES | PROTERA S.R.L. (IT) | 2006-02-09 | — | — | WO | disclosed |
| US-5753221-A | CONTAINING TRIPHOSPHORYLATED NUCLEOSIDE ANALOG WHICH INHIBITS REVERSE TRANSCRIPTASE; VIRICIDES | COMMUNAUTE ECONOMIQUE EUROPEENE (LU) | 1998-05-19 | — | — | US | disclosed |
| EP-0594677-A4 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL INC (US) | 1997-09-17 | — | — | EP | disclosed |
| EP-0517986-B1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | EUROP COMMUNITIES (LU) | 1997-09-10 | — | — | EP | disclosed |
| EP-0594677-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | NeXstar Pharmaceuticals, Inc. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993000910-A1 | ANTIVIRAL LIPONUCLEOSIDES: TREATMENT OF HEPATITIS B | VICAL, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
| WO-1992022306-A1 | TRANSFORMED ERYTHROCYTES, PROCESS FOR PREPARING THE SAME, AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-23 | — | — | WO | disclosed |
| EP-0517986-A1 | Transformed erythrocytes, process for preparing the same, and their use in pharmaceutical compositions | COMMUNAUTE ECONOMIQUE EUROPEENNE (CEE) (LU) | 1992-12-16 | — | — | EP | disclosed |
| EP-0286418-B1 | ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEMS FOR THE SAME | US COMMERCE (US) | 1992-07-08 | — | — | EP | disclosed |
| WO-1988007854-A1 | NEW ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEM | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-10-20 | — | — | WO | disclosed |
| EP-0286418-A1 | Anti-retroviral agents and delivery systems for the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-10-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000821-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | POLG 4737/4885POLB 4023/4885P2RY2 829/4885 |
| US-20220193010-A1 | METHODS OF USING DIPIVEFRIN | QDPR, DNPEP, DPEP1 | POLG 4737/4885POLB 4023/4885P2RY2 829/4885 |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | POLG 42/4885POLB 8/4885P2RY2 2889/4885 |
| US-20110118454-A1 | METHOD FOR PREPARING NUCLEOTIDES AND RELATED ANALOGUES BY SYNTHESIS ON SOLUBLE SUBSTRATE, AND BIOLOGICAL TOOLS THUS PREPARED | PNP, NUDT1, DUT | POLG 585/4885POLB 209/4885P2RY2 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.